Key result
Rivaroxaban linked to similar stroke risk but lower major bleeding vs. warfarin in obese Black patients.
Why the study?
African Americans and obese individuals face increased thrombotic risk, prompting an evaluation of the effectiveness and safety of rivaroxaban versus warfarin in this population with NVAF or VTE.
Does rivaroxaban reduce thrombotic events and bleeding compared to warfarin in obese African Americans with non-valvular atrial fibrillation or venous thromboembolism?
Cohort (n=5,304)
Yes
Does rivaroxaban reduce thrombotic events and bleeding compared to warfarin in obese African Americans with non-valvular atrial fibrillation or venous thromboembolism?
Rivaroxaban appears to be as effective as and potentially safer than warfarin in obese African American patients with NVAF, a subpopulation with inherently elevated thrombotic risk.
Answers are grounded in this paper and cite their sources.
May inform anticoagulation choice in obese African Americans with NVAF; extends evidence to this subgroup but leaves open randomized confirmation.
African Americans (AAs) and obese individuals have increased thrombotic risk. This study evaluated the effectiveness and safety of rivaroxaban versus warfarin in obese, AAs with nonvalvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Optum® De-Identified Electronic Health Record (EHR) data was used to perform separate propensity-score matched analyses of adult, oral anticoagulant (OAC)-naïve AAs with NVAF or acute VTE, respectively; who had a body mass index≥30kg/m 2 and ≥12-months EHR activity with ≥1-encounter before OAC initiation. Cox regression was performed and reported as hazard ratios (HRs) with 95% confidence intervals (CIs). For the NVAF analysis, 1,969 rivaroxaban- and 1,969 warfarin-users were matched. Rivaroxaban was not associated with a difference in stroke/systemic embolism versus warfarin (HR = 0.88, 95%CI = 0.60-1.28), but less major bleeding (HR = 0.68, 95%CI = 0.50-0.94) was observed. Among 683 rivaroxaban-users with VTE, 1:1 matched to warfarin-users, rivaroxaban did not alter recurrent VTE (HR = 1.36, 95%CI = 0.79-2.34) or major bleeding (HR = 0.80, 95%CI = 0.37-1.71) risk versus warfarin at 6-months (similar findings observed at 3- and 12-months). Rivaroxaban appeared to be associated with similar thrombotic, and similar or lower major bleeding risk versus warfarin in these obese, AA cohorts.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2020) conducted a cohort in Non-valvular atrial fibrillation or acute venous thromboembolism (n=5,304). Rivaroxaban vs. Warfarin was evaluated on Stroke or systemic embolism (in NVAF cohort) (HR 0.88, 95% CI 0.60-1.28). Rivaroxaban was associated with a similar risk of stroke or systemic embolism and a lower risk of major bleeding compared to warfarin in obese African Americans with nonvalvular atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: